Coherus BioSciences $150 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market program by Coherus BioSciences, Inc. of shares of thier common stock for up to an aggregate offering price of $150 million. The common stock is listed on the Nasdaq Global Market under the symbol “CHRS.”
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of their portfolio of FDA-approved biosimilars.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Karen Yang. Partner Frank J. Azzopardi and associates Joshua Shirley and Annie Xie provided intellectual property advice. Partner Mario J. Verdolini and associate William Liang provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.